Stent for vessel

Information

  • Patent Grant
  • 6413272
  • Patent Number
    6,413,272
  • Date Filed
    Wednesday, February 28, 2001
    23 years ago
  • Date Issued
    Tuesday, July 2, 2002
    22 years ago
Abstract
A stent for a vessel inserted in use into the vessel of a living body including a tubular member constituting a passageway from one end to its opposite end. The tubular member includes a main mid portion and low tenacity portions formed integrally with both ends of the main mid portion. The low tenacity portions are lower in tenacity than the main mid portion. These low tenacity portions are formed so as to have the Young's modulus approximate to that of the vessel of the living body in which is inserted the stent, so that, when the stent is inserted into the vessel, it is possible to prevent stress concentrated portions from being produced in the vessel.
Description




TECHNICAL FIELD




This invention relates to a stent for a vessel loaded in a vessel, such as blood vessel, lymphoduct, bile duct or urinary duct. The stent for the vessel is used for holding a constant state of the configuration of the vessel when the stent is loaded in the vessel.




BACKGROUND ART




Heretofore, if a constricted portion is produced in the blood vessel, such as artery, a balloon forming portion annexed to near the distal end of a catheter is introduced into the constricted portion in the blood vessel to from a balloon to expand the constricted portion to improve the blood stream, by way of performing a percutaneous blood vessel forming technique (PTA).




Meanwhile, it is known that, if the PTA is applied, the portion which once suffered from constriction tends to undergo re-constriction with a high probability.




For preventing this re-constriction, it is practiced to apply a tubular stent in the portion of the vessel treated with PTA. This stent is buried in an expanded state in a blood vessel


2


as shown in

FIG. 11

to support the blood vessel


2


from its inside to prevent occurrence of re-constriction in the blood vessel


2


.




In clinical cases in which a stent prepared by weaving a linear material of stainless steel in a mesh is introduced in the portion of the vessel treated with PTA, re-constriction occurred in a probability of approximately 15%.




For prohibiting this re-constriction, there is proposed in Japanese Laying-open publication Hei-5-502179 (WO91/01097) a stent prepared by polymer fibers containing a pharmaceutical capable of preventing the constriction from occurring.




Meanwhile, blood re-constriction after loading the stent occurs in a majority of cases at a stent end or beginning from the stent end.




The stent used in the inserted state in the blood vessel holds the blood vessel in the expanded state, so that it is designed to have tenacity sufficiently higher than that of the blood vessel. For example, the blood vessel has a Young's modulus equal to approximately 3×10


7


pascal, whereas the stainless steel as a main material of the stent used for holding the blood vessel in the expanded state is approximately 3×10


11


pascal.




At this time, the blood vessel


2


is reduced in diameter at the portions in register with ends


1




a


,


1




b


of the stent


1


where the blood vessel


2


ceases to be supported by the stent


1


. The portions of the blood vessel


2


supported by the ends


1




a


,


1




b


of the stent


1


represent stress-concentrated portions.




The blood vessel


2


, especially the artery, perpetually performs pulsations to cause the blood to flow. The result is that the load due to the pulsations are repeatedly applied to the stress-concentrated portions of the blood vessel


2


supported by the ends


1




a


,


1




b


of the stent


1


, so that the inner wall of the blood vessel


2


tends to be damaged by the ends


1




a


,


1




b


of the stent


1


. Since the load is applied to the stress-concentrated portions of the blood vessel


2


supported by the ends


1




a


,


1




b


of the stent


1


, there are produced injuries in the inner film or beginning from the inner film to the outer film of the blood vessel


2


. If damaged, the blood vessel


2


recuperates the damaged portion as a reaction proper to a living body. In recuperating the damaged portion, the blood vessel


2


has its inner film multiplied excessively to cause the re-constriction.




DISCLOSURE OF THE INVENTION




It is therefore an object of the present invention to provide a novel stent for a vessel capable of eliminating the drawback of a conventional stent for the vessel.




It is another object of the present invention to provide a stent for a vessel which can positively prevent damages to the vessel whilst it positively keeps the vessel of a living body, such as a blood vessel, in an expanded state.




It is yet another object of the present invention to provide a stent for a vessel which can be inserted in position without producing stress-concentrated portions in the vessel.




For accomplishing the above object, the present invention provides a stent for a vessel, inserted in use into the vessel of a living body, including a tubular member constituting a passageway from one end to the opposite end thereof. The tubular member includes a main mid portion and low tenacity portions formed integrally with both ends of the main mid portion. The low tenacity portions is lower in tenacity than the main mid portion. The low tenacity portions are formed so as to have the Young's modulus approximate to that of the vessel of the living body into which is inserted the stent.




The low tenacity portions are formed by stretching both ends of the tubular member for reducing the thickness thereat.




The low tenacity portions may also be formed by setting the surface density of both ends of the tubular member so as to be lower than that at both ends of the tubular member having a defined value. If the tubular member is prepared by knitting or weaving a fine metal wire or a polymer yarn, the low tenacity portions are formed by lowering the density of the meshes of knitting or weaving on both ends of the tubular member.




The low tenacity portions may also be formed by forming both ends of the tubular member of a material lower in Young's modulus than the material making up the main mid portions.




If the tubular member is formed with a biodegradable polymer material, the stent holds its shape for a few weeks to a few months after insertion into the blood vessel. However, the stent can vanish in about several months after it biologically degrades in the vessel.




If the tubular member is formed by weaving or knitting a fine metal wire or a polymer yarn, the low tenacity portions can be formed on both ends of the tubular member by employing a soft linear material for these ends lower in strength than the linear material making up the main mid portion.











BRIEF DESCRIPTION OF THE DRAWINGS





FIG. 1

is a perspective view showing a stent for a vessel according to the present invention.





FIG. 2

is a cross-sectional view showing the stent for the vessel shown in FIG.


1


.





FIG. 3

is a perspective view showing the state in which the stent shown in

FIG. 1

has been inserted into the blood vessel.





FIG. 4

is a cross-sectional view showing the state in which the stent shown in

FIG. 1

has been inserted into the blood vessel which is undergoing pulsating movements.





FIG. 5



a


is a perspective view showing another embodiment of a stent for a vessel according to the present invention.





FIG. 5



b


is a perspective view showing another embodiment of a stent for a vessel according to the present invention.





FIG. 6

is a perspective view showing yet another embodiment of a stent for a vessel according to the present invention in which low-tenacity portions at the ends of a tubular member are progressively reduced in diameter.





FIG. 7

is a cross-sectional view showing a stent for a vessel of the present invention in which the tubular member is formed of a polymer material.





FIG. 8

is a perspective view showing a stent for a vessel of the present invention in which the tubular member is formed by weaving a fine metal wire or a polymer yarn.





FIG. 9

is a perspective view showing a stent for a vessel of the present invention in which a reinforcement member is provided at a main mid portion of a tubular member formed by weaving a fine metal wire or a polymer yarn.





FIG. 10

is a cross-sectional view showing the fine metal wire or the polymer yarnconstituting the main mid portion of the tubular member.





FIG. 11

is a perspective view showing the state in which a conventional stent for a vessel has been inserted into the blood vessel.











BEST MODE FOR CARRYING OUT THE INVENTION




Referring to the drawings, preferred embodiments of the present invention will be explained in detail.




A stent


11


for a vessel according to the present invention is used as it is inserted into a blood vessel, such as a coronary vessel, and includes a tubular member


12


providing a passageway beginning from its one end to its opposite end, as shown in FIG.


1


. This tubular member


12


is formed of stainless steel having superior corrosion resistance and biological compatibility.




The metals making up the tubular member


12


may be enumerated by a nickel-titanium alloy, platinum, tantalum and platinum, in addition to stainless steel.




The tubular member


12


has a main mid portion


13


having sufficient toughness to hold the blood vessel in the expanded state when the tubular member


12


is inserted into the blood vessel. On both sides of the main mid portion


13


, there are integrally formed low tenacity portions


14


,


15


lower in tenacity than the main mid portion


13


. These low tenacity portions


14


,


15


are formed by setting both ends of the tubular member


12


so as to be smaller in thickness than the main mid portion


13


.




The low tenacity portions


14


,


15


, thus reduced in thickness, are formed by cutting off or forging both ends of the tubular member


12


. At this time, the low tenacity portions


14


,


15


are desirably formed so as to be progressively thinner in thickness from the main mid portion


13


to both ends of thicker thickness. That is, the tubular member


12


is formed with the low tenacity portions


14


,


15


progressively lower in tenacity from the main mid portion


13


to both end portions.




The main mid portion


13


is designed to have a Young's modulus sufficiently larger than that of the blood vessel so that the blood vessel, into which is inserted the stent, will be kept in the expanded state. Since the blood vessel, into which is inserted the stent, has the Young's modulus approximately equal to 3×10


7


pascal, the main mid portion


13


is designed to have the Young's modulus approximately equal to 3×10


11


. The low tenacity portions


14


,


15


are formed so as to have a Young's modulus approximately equal to or slightly larger than that of the blood vessel.




With the stent


11


having the main mid portion


13


of high tenacity, on both ends of which are formed the low tenacity portions


14


,


15


, as described above, the blood vessel


16


can be kept in the expanded state by the high tenacity main mid portion


13


when the stent


11


is inserted in the blood vessel


16


, as shown in FIG.


3


.




The blood flows in the blood vessel


16


through the stent


11


. Also, as the blood vessel


16


repeats expansion and contraction in diameter on pulsations, it applies a load to the stent


11


for reducing its diameter. At this time, the low tenacity portions


14


,


15


formed on both ends of the tubular member


12


readily undergo elastic displacement due to the pulsations of the blood vessel


16


, as shown in FIG.


4


. That is, the low tenacity portions


14


,


15


undergo elastic displacement gradually from the main mid portion


13


towards the ends of the tubular member


12


to prevent stress-concentrated portions from being produced in the blood vessel


16


.




With the above-described stent


11


which, on insertion into the blood vessel


16


, can prohibit generation of the stress-concentrated portions therein, it is possible to prevent damages to the blood vessel


16


and to suppress re-constriction ascribable to the recuperative function of the blood vessel


16


.




By boring plural micro-sized through-holes


16


towards the ends of the tubular member


12


having a uniform wall thickness, as shown in

FIGS. 5



a


and


5




b


, and by reducing the density of the ends of the tubular member


12


as compared to that at the main mid portion


13


, the low tenacity portions


14


,


15


lower in tenacity than the main mid portion


13


are formed at the ends of the tubular member


12


. The number of the micro-sized through-holes


16


of the low tenacity portions


14


,


15


is preferably increased progressively form the main mid portion


13


towards the ends of the tubular member


12


. By boring the micro-sized through-holes


16


in this manner, the low tenacity portions


14


,


15


are lowered in tenacity progressively from the main mid portion


13


towards the-ends of the tubular member


12


.




In addition, by boring the micro-sized through-holes


16


so as to be progressively larger in diameter from the main mid portion


13


towards the ends of the tubular member


12


, the low tenacity portions


14


,


15


may be progressively decreased in tenacity from the main mid portion


13


towards the ends of the tubular member


12


.




The low tenacity portions


14


,


15


formed at the respective ends of the tubular member


12


are preferably reduced in diameter progressively from the main mid portion


13


towards the ends of the tubular member


12


, as shown in FIG.


6


. By this configuration of the tubular member


12


, the portion of the blood vessel


16


expanded by the main mid portion


13


is progressively reduced in diameter to conform to the low tenacity portions


14


,


15


, decreasing in diameter, when the stent


11


is inserted into the blood vessel


16


, thus more positively suppressing occurrence of the stress-concentrated portions.




Although the stent


11


is formed of metal, such as stainless steel, it may also be formed of a polymer material.




A stent


21


, formed of the polymer material, has a tubular member


22


which is molded from the polymer material using an injection molding method or an extrusion molding method, or which is a sheet of a polymer material wrapped into a tube, as shown in FIG.


7


.




The polymer material of the tubular member


22


is selected so as to have biological compatibility and in particular to be biodegradable. The biodegradable materials include, but are not limited to, polylactic acid (PLA), polyglycolic acid (PGA), polyglactin (polyglycolic acid polylactic acid copolymer), polydioxanone, polyglyconate (trimethylene carbonate glycolide copolymer), and a copolymer of polyglycolic acid or polylactic acid Ε-caprolactone. The stent


11


, formed of the biodegradable polymer material, holds its shape for a few weeks to a few months after insertion into the blood vessel, but then degrades and vanishes several months after insertion into the vessel. weeks to a few months after insertion into the blood vessel, can vanish in about several months after insertion by absorption into the living tissue.




The tubular member


22


also has a main mid portion


23


exhibiting toughness sufficient to hold the blood vessel in an expanded state on absorption of the stent


21


into the blood vessel, as shown in FIG.


7


. On both sides of the main mid portion


23


are integrally formed low tenacity portions


24


,


25


lower in tenacity than the main mid portion


23


. These low tenacity portions


24


,


25


are formed by reducing the wall thickness of both ends of the tubular member


22


so as to be thinner than that of the main mid portion


13


.




These thin-walled low tenacity portions


24


,


25


are formed by stretching both ends of the tubular member


22


.




In the stent


21


formed of the polymer material, similarly to the stent


11


of metal, described above, the low tenacity portions


24


,


25


may be formed by boring micro-sized through-holes in both ends of the tubular member


22


. Preferably, the low tenacity portions


24


,


25


are progressively reduced in diameter from the main mid portion


23


towards the ends of the tubular member


22


.




The stent according to the present invention may also be formed by weaving fine metal wires or polymer yarn.




Referring to the drawings, a stent


31


formed of the fine metal wires is explained.




The stent


31


includes a tubular member


33


formed by weaving fine wires


32


of metal exhibiting biological compatibility, such as stainless steel, nickel-titanium alloy, platinum, tantalum or platinum, as shown in FIG.


8


. The tubular member


33


is formed by a number of meshes formed by knitting a sole fine metal wire


32


so as to form loops.




The tubular member


33


has a main mid portion


34


having tenacity sufficient to hold the blood vessel in an expanded state on insertion into the blood vessel. On both ends of the main mid portion


34


are integrally formed low tenacity portions


35


,


36


lower in tenacity than the main mid portion


34


. These low tenacity portions


35


,


36


are formed by using a rougher pitch of the meshes than in the main mid portion


34


having a preset mesh density. At this time, the low tenacity portions


35


,


36


are preferably knitted so as to be progressively lower in mesh density from the main mid portion


34


towards the ends of the tubular member


33


.




It is noted that the main mid portion


34


is knitted so as to have meshes of such density sufficient to realize the Young's modulus sufficiently larger than that of the blood vessel to hold the blood vessel in an expanded state on insertion of the stent


31


in the blood vessel, while the low tenacity portions


35


,


36


are knitted so as to have meshes of such density approximately equal to or slightly larger than that of the blood vessel.




For forming the stent


31


having the low tenacity portions


35


,


36


lower n tenacity than the main mid portion


34


towards the ends of the tubular member


33


, a fine metal wire


32


is knitted to a density such that the tubular member


33


in its entirety has the Young's modulus approximately equal to or slightly larger than that of the blood vessel. The main mid portion


34


of the tubular member


33


is fitted with a reinforcement


37


formed of layered polymer material to increase toughness, at the portion


34


, as shown in FIG.


9


. The polymer materials, making up the reinforcement


37


, are layered so as to have a tenacity sufficient to hold the blood vessel in the expanded state.




The reinforcement


37


is formed by outsert-molding a polymer material on the tubular member


33


formed in turn by weaving the fine metal wire


32


. That is, the reinforcement


37


is formed by injection molding a polymer material on the tubular member


33


placed in a metal mold.




For increasing tenacity of the main mid portion


34


, a fine metal wire


32


may be woven in the main mid portion


34


.




The stent


31


, knitted as shown in

FIG. 8

, may also be formed using polymer yarn. These yarn are formed by spinning polymer fibers.




The stent


31


, formed by the tubular member


33


knitted with biodegradable polymer fibers, holds the knitted state for a few weeks to a few months after insertion into the blood vessel. However, the stent degrades and vanishes into the living tissue of the blood vessel several months after insertion.




The biodegradable polymer includes but is not limited to polylactic acid (PLA), polyglycolic acid (PGA), polyglactin (polyglycolic acid polylactic acid copolymer), polydioxanone, polyglyconate (trimethylene carbonate glycolide copolymer), and a copolymer of polyglycolic acid or polylactic acid Ε-caprolactone.




A variety of pharmaceuticals can be mixed into the yam of polymer fibers. By mixing an X-ray non-permeating agent into the yarn at the time of spinning the fibers, the state of the stent for the vessel, inserted into the blood vessel, can be observed by X-rays. It is also effective to mix thrombus dissolving agents or anti-thrombotic agents, such as heparin, urokinase or t-PA.




The above stent


31


is basically formed by knitting a sole fine metal wire or a sole polymer yarn of a substantially uniform thickness. However, by varying the thickness of the fine metal wire or the yarn, the tubular member


33


may be formed so as to have low tenacity portions


35


,


36


at both ends thereof lower in tenacity than the main mid portion


34


. Specifically, by forming the main mid portion


34


of the tubular member


33


by a thicker metal wire or yarn of higher toughness and by forming the ends of the tubular member


33


from a finer metal wire or yarn of a lower toughness than the metal wire or yarn of the main mid portion


34


, the low tenacity portions


35


,


36


may be formed on both ends of the tubular member


33


.




It is also possible to vary the cross-sectional shape of the fine metal wire or yarn of the main mid portion


34


and that of the fine metal wire or yarn of the ends of the tubular member


33


to form the low tenacity portions


35


,


36


at the ends of the tubular member


33


. That is, by flattening the cross-sectional shape of the fine metal wire or yarn of the ends of the tubular member


33


, for example, it is possible to lower the tenacity thereat. Alternatively, the cross-sectional shape of the fine metal wire


32


or the yarn


42


making up the main mid portion


34


of the tubular member


33


may be set to an H-shape, as shown in

FIG. 10

, for increasing the tenacity of the fine metal wire


32


or the yam


42


making up the main mid portion


34


over that of the fine metal wire or yarn making up the ends of the tubular member


33


.




It is also possible to decrease the number of the fine metal wire or yarn from the main mid portion


34


towards the ends of the tubular member


33


, in order to form the low tenacity portions


35


,


36


at the respective ends of the tubular member


33


when preparing the tubular member


33


by knitting from the metal fine wires r polymer yarn.




The stent according to the present invention can be used not only for the blood vessel but also for other vessels of a living body, such as lymphoduct, bile duct or urinary duct.




Industrial Applicability




With the stent for the vessel according to the present invention, in which low-tenacity portions are formed integrally on both ends of the main mid portion, the vessel can be reliably maintained in an expanded state, while the stress-concentrated portions can be prevented from being produced in the vessel. It is thus possible with the stent for the vessel according to the present invention to prevent inflammation or excess thickening of the vessel and hence re-constriction in the vessel.



Claims
  • 1. A stent for a vessel, inserted in use into the vessel of a living body, comprising:a tubular member having a surface and constituting a passageway from one end to an opposite end thereof; the tubular member comprising a main mid portion and low tenacity portions formed integrally with both ends of the main mid portion, the low tenacity portions being lower in tenacity than the main mid portion; wherein the tubular member includes a plurality of micro-sized holes that are non-uniformly distributed on the surface of the tubular member to reduce a surface density at both ends of the tubular member.
  • 2. A stent for a vessel as claimed in claim 3, wherein the tubular member consists entirely of a polymer material.
  • 3. A stent for a vessel as claimed in claim 2, wherein said polymer material is a biodegradable polymer.
  • 4. A stent for a vessel as claimed in claim 3, wherein said biodegradable polymer is selected from the group consisting of polylactic acid (PLA), polyglycolic acid (PGA), polyglactin (polyglycolic acid polylactic acid copolymer), polydioxanone, polyglyconate (trimethylene carbonate glycolide copolymer), and a copolymer of polyglycolic acid or polylactic acid Ε-caprolactone.
  • 5. A stent for a vessel as claimed in claim 1, wherein a number of micro-sized holes progressively increases from the main mid portion towards the low tenacity portions of the tubular member.
  • 6. A stent for a vessel, inserted in use into the vessel of a living body, comprising:a tubular member constituting a passageway from one end to an opposite end thereof; the tubular member comprising a main mid portion and low tenacity portions formed integrally with both ends of the main mid portion, the low tenacity portions being lower in tenacity than the main mid portion; wherein the tubular member includes a plurality of micro-sized holes, and wherein the micro-sized holes at the lower tenacity portions are larger than the micro-sized holes from the main mid portion to reduce a surface density at both ends of the tubular member.
  • 7. A stent for a vessel according as claimed in claim 6, wherein the tubular member consists entirely of a polymer material.
  • 8. A stent for a vessel as claimed in claim 7, wherein said polymer material is a biodegradable polymer.
  • 9. A stent for a vessel as claimed in claim 8, wherein said biodegradable polymer is selected from the group consisting of polylactic acid (PLA), polyglycolic acid (PGA), polyglactin (polyglycolic acid polylactic acid copolymer), polydioxanone, polyglyconate (trimethylene carbonate glycolide copolymer), and a copolymer of polyglycolic acid or polylactic acid Ε-caprolactone.
Priority Claims (1)
Number Date Country Kind
9-078682 Mar 1997 JP
Parent Case Info

This application is a divisional of application Ser. No. 09/194,262 filed on Jan. 29, 1999, now U.S. Pat. No. 6,200,335 which is a 371 of PCT/JP98/01989 Mar. 31, 1998.

US Referenced Citations (7)
Number Name Date Kind
5064435 Porter Nov 1991 A
5366504 Andersen et al. Nov 1994 A
5522883 Slater et al. Jun 1996 A
5674276 Andersen et al. Oct 1997 A
5836966 St. Germain Nov 1998 A
6007574 Pulnev et al. Dec 1999 A
6241757 An et al. Jun 2001 B1
Foreign Referenced Citations (4)
Number Date Country
7-509152 Oct 1995 JP
8-196642 Aug 1996 JP
WO-9514500 Jun 1995 WO
WO9517859 Jul 1995 WO